A review of targeted drugs for NF2-related tumors
Original title: The effectiveness of targeted therapy in the treatment of patients with neurofibromatosis type 2-related schwannomatosis and vestibular schwannomas: A systematic review.
How far along is this research?
- Lab cells
- Animals
- Review
- Tested in people
This looks across many earlier studies rather than running a new one.
This is a summary of studies that already exist, not a new result, though some of these drugs are used in people now.
The short version
Researchers looked at all the studies on drugs that may slow the hearing nerve tumors caused by NF2.
What was studied. Researchers gathered and reviewed 12 earlier studies with 426 patients who had NF2-related schwannomatosis. The patients had been treated with targeted drugs instead of surgery or radiation.
What they found. The 12 studies included 6 clinical trials, 2 other reviews, and 4 case reports. Bevacizumab was studied the most. In those studies it held tumors steady, helped protect hearing, and kept quality of life steady. Other drugs, like everolimus, vistusertib, brigatinib, and anlotinib, mostly kept the disease from growing. Serious side effects were uncommon across the studies, and no deaths were caused by treatment.
What this means, and what it doesn't
What it could mean: For some people with NF2, a drug taken by mouth or by infusion may be an option that protects hearing and function, instead of surgery or radiation. Some of these drugs are already given to patients today. If you have NF2, this is worth asking your doctor or a specialist center about.
What it doesn't mean: This is not a cure. It is a review of studies that already happened, not a new treatment or a new result. Most of the studies were small, and some were reports on just one person. The authors say larger trials at many hospitals are still needed to know how well these drugs work over time and what dose is best. Holding a tumor steady is not the same as making it go away.
Source: PubMed, February 25, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.